Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1814, Issue 12, 2011, Pages 1947-1954

  Meininger, David ^a,c   Zalameda, Leeanne ^b   Liu, Yichin ^b,d   Stepan, Lara P ^a   Borges, Luis ^a   McCarter, John D ^b   Sutherland, Claire L ^a  

^a AMGEN INC   (United States)

^b AMGEN INC   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d GENENTECH INC   (United States)

Author keywords

Human; IDO1; IDO2; Inhibition; Kinetics

Indexed keywords

AMG 1; DIOXYGENASE; ENZYME INHIBITOR; INDOLEAMINE 2,3 DIOXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE 1 INHIBITOR; INDOLEAMINE 2,3 DIOXYGENASE 2; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME PURIFICATION; ENZYME STRUCTURE; HIGH THROUGHPUT SCREENING; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL;

DRUG DISCOVERY; ENZYME INHIBITORS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; ISOENZYMES; KINETICS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

EID: 81755161497     PISSN: 15709639     EISSN: 18781454     Source Type: Journal    
DOI: 10.1016/j.bbapap.2011.07.023     Document Type: Article

References (40)

1. O. Takikawa, R. Yoshida, R. Kido, and O. Hayaishi Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase J. Biol. Chem. 261 1986 3648 3653 (Pubitemid 17200663)
2. O. Takikawa Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated l-tryptophan metabolism Biochem. Biophys. Res. Commun. 338 2005 12 19 (Pubitemid 41540531)
3. X. Dai, and B.T. Zhu Indoleamine 2,3-dioxygenase tissue distribution and cellular localization in mice: implications for its biological functions J. Histochem. Cytochem. 58 2010 17 28
4. A.M. Hansen, C. Driussi, V. Turner, O. Takikawa, and N.H. Hunt Tissue distribution of indoleamine 2,3-dioxygenase in normal and malaria-infected tissue Redox. Rep. 5 2000 112 115 (Pubitemid 30487979)
5. T. Hayashi, L. Beck, C. Rossetto, X. Gong, O. Takikawa, K. Takabayashi, D.H. Broide, D.A. Carson, and E. Raz Inhibition of experimental asthma by indoleamine 2,3-dioxygenase J. Clin. Invest. 114 2004 270 279 (Pubitemid 39071632)
6. D.H. Munn, M. Zhou, J.T. Attwood, I. Bondarev, S.J. Conway, B. Marshall, C. Brown, and A.L. Mellor Prevention of allogeneic fetal rejection by tryptophan catabolism Science 281 1998 1191 1193 (Pubitemid 28406294)
7. T.W. Stone, G.M. Mackay, C.M. Forrest, C.J. Clark, and L.G. Darlington Tryptophan metabolites and brain disorders Clin. Chem. Lab. Med. 41 2003 852 859 (Pubitemid 37010175)
8. A. Macchiarulo, E. Camaioni, R. Nuti, and R. Pellicciari Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease Amino Acids 37 2009 219 229
9. S. Lob, A. Konigsrainer, H.G. Rammensee, G. Opelz, and P. Terness Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat. Rev. Cancer 9 2009 445 452
10. G. Frumento, R. Rotondo, M. Tonetti, G. Damonte, U. Benatti, and G.B. Ferrara Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase J. Exp. Med. 196 2002 459 468
11. M.P. Colombo, and S. Piconese Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy Nat. Rev. Cancer 7 2007 880 887 (Pubitemid 350006256)
12. F. Fallarino, U. Grohmann, S. You, B.C. McGrath, D.R. Cavener, C. Vacca, C. Orabona, R. Bianchi, M.L. Belladonna, C. Volpi, P. Santamaria, M.C. Fioretti, and P. Puccetti The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells J. Immunol. 176 2006 6752 6761 (Pubitemid 43787857)
13. Y. Kudo, and C.A. Boyd The physiology of immune evasion during pregnancy; the critical role of placental tryptophan metabolism and transport Pflugers Arch. 442 2001 639 641 (Pubitemid 32783671)
14. A.L. Mellor, and D.H. Munn Tryptophan catabolism prevents maternal T cells from activating lethal anti-fetal immune responses J. Reprod. Immunol. 52 2001 5 13 (Pubitemid 32916375)
15. W.E. Knox The regulation of tryptophan pyrrolase activity by tryptophan Adv. Enzyme Regul. 4 1966 287 297
16. M. Takao, A. Okamoto, T. Nikaido, M. Urashima, S. Takakura, M. Saito, S. Okamoto, O. Takikawa, H. Sasaki, M. Yasuda, K. Ochiai, and T. Tanaka Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of ovarian cancer Oncol. Rep. 17 2007 1333 1339
17. A. Okamoto, T. Nikaido, K. Ochiai, S. Takakura, M. Saito, Y. Aoki, N. Ishii, N. Yanaihara, K. Yamada, O. Takikawa, R. Kawaguchi, S. Isonishi, T. Tanaka, and M. Urashima Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells Clin. Cancer Res. 11 2005 6030 6039 (Pubitemid 41170335)
18. G. Brandacher, A. Perathoner, R. Ladurner, S. Schneeberger, P. Obrist, C. Winkler, E.R. Werner, G. Werner-Felmayer, H.G. Weiss, G. Gobel, R. Margreiter, A. Konigsrainer, D. Fuchs, and A. Amberger Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells Clin. Cancer Res. 12 2006 1144 1151 (Pubitemid 43342502)
19. K. Ino, E. Yamamoto, K. Shibata, H. Kajiyama, N. Yoshida, M. Terauchi, A. Nawa, T. Nagasaka, O. Takikawa, and F. Kikkawa Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival Clin. Cancer Res. 14 2008 2310 2317 (Pubitemid 351551062)
20. K. Ino, N. Yoshida, H. Kajiyama, K. Shibata, E. Yamamoto, K. Kidokoro, N. Takahashi, M. Terauchi, A. Nawa, S. Nomura, T. Nagasaka, O. Takikawa, and F. Kikkawa Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer Br. J. Cancer 95 2006 1555 1561 (Pubitemid 44863359)
21. C. Uyttenhove, L. Pilotte, I. Theate, V. Stroobant, D. Colau, N. Parmentier, T. Boon, and B.J. Van den Eynde Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase Nat. Med. 9 2003 1269 1274 (Pubitemid 37279849)
22. A.J. Muller, J.B. DuHadaway, P.S. Donover, E. Sutanto-Ward, and G.C. Prendergast Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy Nat. Med. 11 2005 312 319 (Pubitemid 40460560)
23. X. Liu, N. Shin, H.K. Koblish, G. Yang, Q. Wang, K. Wang, L. Leffet, M.J. Hansbury, B. Thomas, M. Rupar, P. Waeltz, K.J. Bowman, P. Polam, R.B. Sparks, E.W. Yue, Y. Li, R. Wynn, J.S. Fridman, T.C. Burn, A.P. Combs, R.C. Newton, and P.A. Scherle Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity Blood 115 2010 3520 3530
24. E.W. Yue, B. Douty, B. Wayland, M. Bower, X. Liu, L. Leffet, Q. Wang, K.J. Bowman, M.J. Hansbury, C. Liu, M. Wei, Y. Li, R. Wynn, T.C. Burn, H.K. Koblish, J.S. Fridman, B. Metcalf, P.A. Scherle, and A.P. Combs Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model J. Med. Chem. 52 2009 7364 7367
25. Y. Wang, H. Liu, G. McKenzie, P.K. Witting, J.P. Stasch, M. Hahn, D. Changsirivathanathamrong, B.J. Wu, H.J. Ball, S.R. Thomas, V. Kapoor, D.S. Celermajer, A.L. Mellor, J.F. Keaney Jr., N.H. Hunt, and R. Stocker Kynurenine is an endothelium-derived relaxing factor produced during inflammation Nat. Med. 16 2010 279 285
26. E. Kwidzinski, and I. Bechmann IDO expression in the brain: a double-edged sword J. Mol. Med. 85 2007 1351 1359 (Pubitemid 350234090)
27. S. Vazquez, J.A. Aquilina, J.F. Jamie, M.M. Sheil, and R.J. Truscott Novel protein modification by kynurenine in human lenses J. Biol. Chem. 277 2002 4867 4873 (Pubitemid 34968522)
28. O. Takikawa, T.K. Littlejohn, and R.J. Truscott Indoleamine 2,3-dioxygenase in the human lens, the first enzyme in the synthesis of UV filters Exp. Eye Res. 72 2001 271 277 (Pubitemid 32977980)
29. T. Di Pucchio, S. Danese, R. De Cristofaro, and S. Rutella Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds Expert Opin. Ther. Pat. 20 2010 229 250
30. C.J. Austin, B.M. Mailu, G.J. Maghzal, A. Sanchez-Perez, S. Rahlfs, K. Zocher, H.J. Yuasa, J.W. Arthur, K. Becker, R. Stocker, N.H. Hunt, and H.J. Ball Biochemical characteristics and inhibitor selectivity of mouse indoleamine 2,3-dioxygenase-2 Amino Acids 39 2010 565 578
31. H.J. Ball, A. Sanchez-Perez, S. Weiser, C.J. Austin, F. Astelbauer, J. Miu, J.A. McQuillan, R. Stocker, L.S. Jermiin, and N.H. Hunt Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice Gene 396 2007 203 213 (Pubitemid 46818792)
32. R. Metz, J.B. Duhadaway, U. Kamasani, L. Laury-Kleintop, A.J. Muller, and G.C. Prendergast Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound d-1-methyl-tryptophan Cancer Res. 67 2007 7082 7087 (Pubitemid 47206533)
33. H.J. Yuasa, M. Takubo, A. Takahashi, T. Hasegawa, H. Noma, and T. Suzuki Evolution of vertebrate indoleamine 2,3-dioxygenases J. Mol. Evol. 65 2007 705 714
34. M.F. Murray The human indoleamine 2,3-dioxygenase gene and related human genes Curr. Drug Met. 8 2007 197 200 (Pubitemid 46621669)
35. H.J. Ball, H.J. Yuasa, C.J. Austin, S. Weiser, and N.H. Hunt Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway Int. J. Biochem. Cell Biol. 41 2009 467 471
36. O. Takikawa, T. Kuroiwa, F. Yamazaki, and R. Kido Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity J. Biol. Chem. 263 1988 2041 2048 (Pubitemid 18052167)
37. C.J. Austin, J. Mizdrak, A. Matin, N. Sirijovski, P. Kosim-Satyaputra, R.D. Willows, T.H. Roberts, R.J. Truscott, G. Polekhina, M.W. Parker, and J.F. Jamie Optimised expression and purification of recombinant human indoleamine 2,3-dioxygenase Protein Expr. Purif. 37 2004 392 398 (Pubitemid 39187977)
38. H.J. Yuasa, H.J. Ball, Y.F. Ho, C.J. Austin, C.M. Whittington, K. Belov, G.J. Maghzal, L.S. Jermiin, and N.H. Hunt Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases IDOs from monotremes and marsupials Comp. Biochem. Physiol. B 153 2009 137 144
39. O. Takikawa, Y. Tagawa, Y. Iwakura, R. Yoshida, and R.J. Truscott Interferon-gamma-dependent/independent expression of indoleamine 2,3-dioxygenase, studies with interferon-gamma-knockout mice Adv. Exp. Med. Biol. 467 1999 553 557
40. S. Lob, A. Konigsrainer, R. Schafer, H.G. Rammensee, G. Opelz, and P. Terness Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells Blood 111 2008 2152 2154 (Pubitemid 351451527)